|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 2 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 3 | Reliability and Validity of the Functional Analysis Screening Tool 显示文摘 | lwata Brian A Deleon Iser G Roscoe Eileen M | 2013 | Journal of Applied Behavior Analysis2013，，46： | 1 |
| 4 | Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study显示文摘 | Jean-Michel Molina Chloe Orkin David M Iser Francisco-Xavier Zamora Mark Nelson Christoph Stephan Benedetta Massetto Anuj Gaggar Liyun Ni Evguenia Svarovskaia Diana Brainard G Mani Subramanian John G McHutchison Massimo Puoti Jürgen K Rockstroh | 2015 | The Lancet . 2015 (9973)2015，，9973： | 1 |
| 5 | Results of intracoronary recombinant human vascular growth factor(rhVEGF) administration trial显示文摘 | Henry T D Rocha-Singh K Iser J M a al | 1998 | J Am Coll Cardiol1998，31，： | 1 |
| 6 | Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers显示文摘 | Thompson AJ Nguyen T Iser D Ayres A Jackson K Littlejohn M Slavin J Bowden S Gane EJ Abbott W | | 0，，06： | 1 |
| 7 | Non‐cirrhotic portal hypertension in HIV mono‐infected patients显示文摘 | Belinda D Jackson Joseph S Doyle Jennifer F Hoy Stuart K Roberts John Colman Margaret E Hellard Joseph J Sasadeusz David M Iser | 2012 | Journal of Gastroenterology and Hepatology2012，，9： | 1 |
| 8 | Stable transformation of sunflower using a non - meristematic regeneration protocol and green fluorescent protein as a vital marker 显示文摘 | Muller A Iser M Hess D | 2001 | Transgenic Res2001，10，5： | 1 |
| 9 | Renal microvascular actios kf calcitonin gene-ralated peptide显示文摘 | RESLEROVA M LOUTZENH ISER R | 1998 | Am J Physiol1998，274，62： | 1 |
| 10 | Stable transformation of sunflower using a non-meristematic regeneration protocol and green fluorescent protein as a vital marker显示文摘 | Muller A Iser M Hess D | 2001 | Transgenic Res2001，10，5： | 1 |
| 11 | The Local Perturbation Method for Solving the Problem of Diffraction from a Surface with Small Slope Irregularities 显示文摘 | Isers A B Puzenko A A Fuks I M | 1991 | J Electromagn Wave Appl1991，，5： | 1 |
| 12 | Generalized crack initiation and crack damage stress thresholds of brittle rock masses near underground excavations显示文摘 | CAI M ISER P K SAKA Y | 2004 | International Journal of Rock Mechanics and Mining Sciences2004，41，5： | 1 |
| 13 | Fatty liver disease--a practical guide for GPs 显示文摘 | Iser D Ryan M | 2013 | Aust Faro Physician2013，42，7： | 1 |
| 14 | Glycine residues in potassium channel-like selectivity filters determine potassium selectivity in four-loop-per-subunit HKT transporters from plants显示文摘 | M/iser P Hosoo Y Goshima S | 2002 | Proceedings of the Na tional Academy of Sciences USA2002，99，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员